Anticancer research on the plant species Rhodiola rosea L. (Crassulaceae) has begun in animal models in 1987. In combination with cyclophosphamide, R. rosea extract enhanced the anti-tumor and anti-metastatic effects of drug treatment and reduced drug-induced toxicity. Combined with Adriamycin®, it improved inhibition of tumor dissemination and prevented liver toxicity. The aim of the present work was to study the effect of rosavin and aqueous and 50% hydroalcoholic extracts of R. rosea roots and rhizomes on neovascular reaction induced in the skin of Balb/c mice after grafting of L-1 sarcoma cells. Mice were treated per os with 50, 100, 200 and 400 µg of extracts, or were fed rosavin in daily doses 2, 4 and 8 µg. After 72 hours mice were sacrificed with lethal dose of Morbital. All newly formed blood vessels were identified and counted in dissection microscope. Both extracts in 100-400 µg daily doses and rosavin in the highest dose highly significantly decreased neovascular reaction.